Prinbury Biopharm Co., Ltd. (“Prinbury”), a biopharmaceutical R&D company wholly owned by PRINJOHNSON BIOPHARM INC, was established in 2009 . We have nearly 100 employees, over 70% of whom hold master’s or higher degrees, and possess R&D equipment worth nearly RMB 50 million in our 3,000-square-meter R&D space.
Certified as a “National High-tech Enterprise”, Prinbury is mainly engaged in the R&D of high-value prescription products and the registration of these products in the United States, China, and other markets worldwide. Through strategic cooperation with globally renowned pharmaceutical companies, we are devoted to the R&D of small-molecule chemical drug formulations used for the treatment of cardiovascular disease, depression, diabetes, cancers, viral diseases, senile dementia, schizophrenia, pain, cough, etc. In addition to traditional oral solid and liquid immediate-release preparations, our drugs and preparations also include complex preparations such as topical pharmaceutical products, Patches,nano preparations, and oral sustained and controlled release preparations.
Prinbury collaborate with Top 500 and well-known pharmaceutical companies to support the R&D activities. In the future, we will serve the medical health and welfare of people in China and around the world by continuously expanding and upgrading our drug preparations and delivery system technology platforms and conducting comprehensive research and development of drug preparations to meet the unmet needs of patients worldwide.